Watch MGX. Know when insiders buy.
One email the day a filing lands. Free.
MGX
Metagenomi Therapeutics, Inc.
1.16
+0.01 +0.87%
USD · close Sep 10
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · insiders 50, shorts 57
Insiders, 90 days
−$5K
net selling · 0 buys, 2 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $43.8MP/E —DIV YIELD —FCF YIELD -195.79%REV TTM —NET INCOME −$93.5MNET CASH —52W 1.14 – 3.35SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$28.8M | −$27.5M | — | -0.73 | −$19.5M | $125K | −$19.6M | Aug 10 |
| Q1 2026 · Mar 31 | $1.2M | −69.8% | — | −$24.6M | −$23.1M | — | -0.61 | −$21.2M | $25K | −$21.2M | Aug 10 |
| Q4 2025 · Dec 31derived | $3.9M | −59.3% | — | −$24.4M | −$22.5M | — | -0.60 | −$23.5M | $85K | −$23.6M | Mar 5 |
| Q3 2025 · Sep 30 | $8.7M | −24.8% | — | −$22.8M | −$20.4M | — | -0.55 | −$21.3M | $74K | −$21.3M | Nov 12 |
| Q2 2025 · Jun 30 | $8.5M | −57.5% | — | −$21M | −$19.9M | — | -0.54 | −$21.3M | $127K | −$21.4M | Aug 10 |
| Q1 2025 · Mar 31 | $4.1M | −63.0% | — | −$27.8M | −$25M | — | -0.68 | −$22.8M | $288K | −$23.1M | Aug 10 |
| Q4 2024 · Dec 31derived | $9.6M | −22.5% | — | −$20.6M | −$23.4M | — | -0.63 | −$26.3M | $334K | −$26.6M | Mar 5 |
| Q3 2024 · Sep 30 | $11.5M | −6.9% | — | −$22.4M | −$18.8M | — | -0.51 | −$26.6M | $1.2M | −$27.8M | Nov 12 |
| Q2 2024 · Jun 30 | $20M | — | — | −$16.9M | −$10.7M | — | -0.29 | −$26.3M | $665K | −$27M | Nov 12 |
| Q1 2024 · Mar 31 | $11.2M | — | — | −$29M | −$25.1M | — | -1.19 | −$29.9M | $915K | −$30.8M | Nov 12 |
| Q4 2023 · Dec 31derived | $12.4M | — | — | −$20.2M | −$19.3M | — | -5.67 | −$20.6M | $1.7M | −$22.3M | Mar 17 |
| Q3 2023 · Sep 30 | $12.4M | — | — | −$22.4M | −$19.8M | — | -5.82 | −$23.7M | $2.3M | −$26M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $25.2M | — | −$96M | −$87.9M | -348.5% | -2.36 | −$88.9M | $574K | −$89.5M | — | — |
| FY2024 · to Dec 31 | $52.3M | — | −$88.9M | −$78.1M | -149.3% | -2.36 | −$109.1M | $3.1M | −$112.2M | — | — |
| FY2023 · to Dec 31 | $44.8M | — | −$78.5M | −$68.3M | -152.5% | -20.05 | −$91.4M | $9.8M | −$101.2M | — | — |
Every number comes from Metagenomi Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.